Inhibition of hepatic drug metabolism by cyclic 3',5'-adenosine monophosphate.
D000814:Aniline Compounds / Q000037:antagonists & inhibitors; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism; D005934:Glucagon / Q000494:pharmacology; D006591:Hexobarbital / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010477:Perfusion; D051381:Rats; D012890:Sleep / Q000187:drug effects; D013217:Starvation / Q000378:metabolism; D013806:Theophylline / Q000494:pharmacology; D013997:Time Factors
D000814:Aniline Compounds; D007328:Insulin; D003994:Bucladesine; D005934:Glucagon; D006591:Hexobarbital; D013806:Theophylline; D000242:Cyclic AMP